Month: August 2024

AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9th and 10th. H.C. Wainwright 26th Annual Global Investment Conference: September 9th – 11th  Title: Lumos Pharma Corporate Presentation (On-Demand)  Date/Time: September 9th at 7:00AM EDT  Webcast Link: Register here  1×1 Meetings: Monday-Tuesday, September 9th-10th     The presentation webcast can be downloaded at 7:00AM EDT on September 9th and will be available for 90 days thereafter....

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. The reverse stock split will become effective at 12:01 am ET on Monday, August 19, 2024. The Company’s common stock is expected begin trading on the Nasdaq Capital Market under the same symbol (ALGS) on a split-adjusted basis at the market open on August 19, 2024 with the new CUSIP number 01626L 204. At the effective time, all outstanding stock options, warrants, and equity incentive plans will be proportionally affected. Every 25 shares of issued and outstanding shares...

Glucotrack ADCES poster highlights over 50% of surveyed diabetes patients are open to new Continuous Blood Glucose Monitor concept Rutherford, NJ, Aug. 15, 2024 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology innovator focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced new findings from a recent market research study evaluating the acceptance of its new Continuous Blood Glucose Monitor (CBGM) concept among people with insulin-requiring diabetes. The poster was presented at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference held Aug. 9-12, 2024, in New Orleans. The study, conducted with a diverse group of participants, revealed that over 50% of respondents are open...

EDMONTON, Alberta, Aug. 15, 2024 (GLOBE NEWSWIRE) — Capital Power Corporation (“Capital Power”, the “Company”, “we”, “us” or “our”) (TSX: CPX) announced today the completion of a previously announced solicitation of consents (the “Consent Solicitation”) from holders (“Holders”) of its C$350M 7.95% Fixed-to-Fixed Rate Subordinated Notes, Series 1, due September 9, 2082 (the “Series 1 Notes”). Based on the report of the tabulation agent for the Consent Solicitation, the Consent Solicitation received strong support and was approved by Holders, significantly exceeding the required threshold of at least 66 2/3% of the aggregate outstanding principal amount of the Series 1 Notes. As a result, the extraordinary resolution authorizing certain proposed amendments to the indenture governing the Series 1 Notes has been approved. The proposed...

Reno, Nevada, Aug. 15, 2024 (GLOBE NEWSWIRE) — Nevada Canyon Gold Corp. (OTC Markets: NGLD) (The “Company” or “Nevada Canyon”) is pleased to announce through its wholly-owned subsidiary, Nevada Canyon, LLC, that it has amended and exercised its Option to Purchase Agreement (the “Agreement”) with Target Minerals, Inc (“Target”), a private Nevada company, and acquired one-hundred percent (100%) interest of Target’s one percent (1%) production royalty on the Olinghouse Project, located in the Olinghouse Mining District, Washoe County, Nevada.The Olinghouse Project is located approximately 30 miles east of Reno, Nevada. The property was operated by Alta Gold in the late 1990’s and Alta completed a feasibility study in 1997. The Olinghouse Project hosts an historic geologic resource (Alta Gold Feasibility Study 1997) based on over...

RIVERSIDE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) — SolarMax Technology, Inc. (Nasdaq SMXT) (“SolarMax” or the “Company”), an integrated solar energy company, signed a non-binding term sheet for a significant new commercial solar project in California. The project, a major mall in the San Jose area, represents another step forward in SolarMax’ ongoing strategy to expand its solar development capabilities in the US commercial market. The proposed California project is to include the development and management of a 4.17 megawatt (MW) photovoltaic solar power plant and a 2.0 MW energy storage system. As part of the project, SolarMax will also oversee the replacement of the mall’s roof to support the new solar infrastructure. “A key component of our strategic growth plans is the expansion of our commercial solar development services...

Company to Discuss Recent Mpox Developments as Well as Milestones Related to theBARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to present at the next Emerging Growth Conference being held August 21-22, 2024. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s Chairman and CEO, David Dodd, in real time. Mr. Dodd will be presenting at 4:10pm ET on Wednesday, August 21, 2024. Following his presentation, Mr. Dodd will open the floor for questions, time permitting. Please submit your questions...